DE69636122D1 - Verfahren zur einführung von genen in zielzellen mit hilfe von retroviren - Google Patents

Verfahren zur einführung von genen in zielzellen mit hilfe von retroviren

Info

Publication number
DE69636122D1
DE69636122D1 DE69636122T DE69636122T DE69636122D1 DE 69636122 D1 DE69636122 D1 DE 69636122D1 DE 69636122 T DE69636122 T DE 69636122T DE 69636122 T DE69636122 T DE 69636122T DE 69636122 D1 DE69636122 D1 DE 69636122D1
Authority
DE
Germany
Prior art keywords
retrovirus
target cells
help
effective amount
functional material
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69636122T
Other languages
English (en)
Other versions
DE69636122T2 (de
Inventor
Kiyozo Asada
Takashi Uemori
Takashi Ueno
Nobuto Koyama
Kimikazu Hashino
Ikunoshiu Kato
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takara Bio Inc
Original Assignee
Takara Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takara Bio Inc filed Critical Takara Bio Inc
Publication of DE69636122D1 publication Critical patent/DE69636122D1/de
Application granted granted Critical
Publication of DE69636122T2 publication Critical patent/DE69636122T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1085—Transferases (2.) transferring alkyl or aryl groups other than methyl groups (2.5)
    • C12N9/1088—Glutathione transferase (2.5.1.18)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13045—Special targeting system for viral vectors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE69636122T 1995-11-13 1996-11-07 Verfahren zum gentransfer in zielzellen mit einem retrovirus Expired - Lifetime DE69636122T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP29438295 1995-11-13
JP29438295 1995-11-13
JP5184796 1996-03-08
JP5184796 1996-03-08
PCT/JP1996/003254 WO1997018318A1 (en) 1995-11-13 1996-11-07 Method for gene introduction into target cells by retrovirus

Publications (2)

Publication Number Publication Date
DE69636122D1 true DE69636122D1 (de) 2006-06-14
DE69636122T2 DE69636122T2 (de) 2006-12-07

Family

ID=26392431

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69636122T Expired - Lifetime DE69636122T2 (de) 1995-11-13 1996-11-07 Verfahren zum gentransfer in zielzellen mit einem retrovirus

Country Status (13)

Country Link
US (5) US6472204B1 (de)
EP (1) EP0870839B1 (de)
JP (1) JP3343357B2 (de)
KR (2) KR100395420B1 (de)
CN (1) CN100390290C (de)
AT (1) ATE325884T1 (de)
AU (1) AU709831B2 (de)
CA (1) CA2235629A1 (de)
DE (1) DE69636122T2 (de)
EA (3) EA003195B1 (de)
ES (1) ES2259182T3 (de)
MX (1) MX9803706A (de)
WO (1) WO1997018318A1 (de)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7083979B1 (en) 1994-03-25 2006-08-01 Indiana University Foundation Methods for enhanced retroviral-mediated gene transfer
JP4051416B2 (ja) 1995-06-15 2008-02-27 クルーセル ホランド ベスローテン フェンノートシャップ 遺伝子治療に使用されるヒト組換えアデノウイルス用のパッケージングシステム
KR100793625B1 (ko) * 1995-09-29 2008-01-11 인디아나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 바이러스-매개된 ｄｎａ 전달을 향상시키는 방법에 의해생산된 생존성 세포 집단 및 이를 포함하는 세포 조성물
TWI239352B (en) * 1997-07-23 2005-09-11 Takara Bio Inc Gene transfer method with the use of serum-free medium
ATE426036T1 (de) * 1997-11-14 2009-04-15 Cedars Sinai Medical Center Transfektion und transfer nicht humaner mannlicher keimzellen zur generierung transgener nicht humaner saugetiere
DE69934690T2 (de) 1998-07-01 2007-11-15 Takara Bio Inc., Otsu Gentransfermethoden
CA2348736A1 (en) * 1998-10-31 2000-05-11 University Of Medicine And Dentistry Of New Jersey A myeloid precursor cell useful for gene therapy and for modulation of immune responses
DE60036929T2 (de) * 1999-03-23 2008-08-07 Takara Bio Inc., Otsu Gentherapeutika
US7410941B1 (en) 1999-04-13 2008-08-12 The Kenneth S. Warren Institute, Inc. Methods for treatment of neurodegenerative conditions by peripherally administered erythropoietin
US7345019B1 (en) 1999-04-13 2008-03-18 The Kenneth S. Warren Institute, Inc. Modulation of excitable tissue function by peripherally administered erythropoietin
US20050170463A1 (en) * 1999-04-15 2005-08-04 Abraham Bout Recombinant protein production in permanent amniocytic cells that comprise nucleic acid encoding adenovirus E1A and E1B proteins
US8236561B2 (en) * 1999-04-15 2012-08-07 Crucell Holland B.V. Efficient production of IgA in recombinant mammalian cells
US6855544B1 (en) * 1999-04-15 2005-02-15 Crucell Holland B.V. Recombinant protein production in a human cell
US7604960B2 (en) * 1999-04-15 2009-10-20 Crucell Holland B.V. Transient protein expression methods
US20050164386A1 (en) * 1999-04-15 2005-07-28 Uytdehaag Alphonsus G. Overexpression of enzymes involved in post-translational protein modifications in human cells
US7297680B2 (en) 1999-04-15 2007-11-20 Crucell Holland B.V. Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content
GB9912965D0 (en) * 1999-06-03 1999-08-04 Oxford Biomedica Ltd In vivo selection method
WO2001004332A1 (en) * 1999-07-08 2001-01-18 Burkhard Hennemann Method to improve viral infection
US7521220B2 (en) * 1999-11-26 2009-04-21 Crucell Holland B.V. Production of vaccines
US7192759B1 (en) 1999-11-26 2007-03-20 Crucell Holland B.V. Production of vaccines
US7527961B2 (en) * 1999-11-26 2009-05-05 Crucell Holland B.V. Production of vaccines
AU2001285263A1 (en) 2000-08-25 2002-03-13 The General Hospital Corporation Selective precipitation of viruses
US6531121B2 (en) 2000-12-29 2003-03-11 The Kenneth S. Warren Institute, Inc. Protection and enhancement of erythropoietin-responsive cells, tissues and organs
PA8536201A1 (es) 2000-12-29 2002-08-29 Kenneth S Warren Inst Inc Protección y mejoramiento de células, tejidos y órganos que responden a la eritropoyetina
DE60232149D1 (de) 2001-06-20 2009-06-10 Dainippon Sumitomo Pharma Co Verfahren zur förderung des nukleinsäuretransfers
JP2005052001A (ja) * 2001-07-05 2005-03-03 Takara Bio Inc 遺伝子治療剤
US7910368B2 (en) 2001-08-15 2011-03-22 Takara Bio Inc. Method of extended culture for antigen-specific cytotoxic lymphocytes
NZ533124A (en) * 2001-12-07 2005-11-25 Crucell Holland B Production of viruses, viral isolates and vaccines
CN100591760C (zh) 2002-03-25 2010-02-24 宝生物工程株式会社 制备细胞毒性淋巴细胞的方法
WO2011063477A1 (en) * 2009-11-30 2011-06-03 Queensland University Of Technology Fibronectin: growth factor chimeras
US20100143442A1 (en) 2003-02-05 2010-06-10 Queensland University Of Technology Growth factor complexes and modulation of cell migration and growth
US20040220085A1 (en) * 2003-05-02 2004-11-04 Jasbir Sandhu Compositions for nucleic acid delivery
US20040219099A1 (en) * 2003-05-02 2004-11-04 Jasbir Sandhu Method for the treatment of tumors
CN100383238C (zh) 2003-05-09 2008-04-23 克鲁塞尔荷兰公司 E1-永生化的细胞培养物及培养所述细胞以提高从中获取的产物产量的方法
EP1626992B1 (de) * 2003-05-23 2010-06-02 Crucell Holland B.V. Herstellung von rekombinanten igm in den per.c6 zellen
FR2857598A1 (fr) * 2003-07-18 2005-01-21 Inst Nat Sante Rech Med Composes anti-angiogeniques, composition pharmaceutique les comprenant, et leur utilisation
US8927273B2 (en) 2003-08-22 2015-01-06 Takara Bio Inc. Process for producing cytotoxic lymphocytes
GB0410130D0 (en) * 2004-05-06 2004-06-09 Molmed Spa Cell preparation
CN101031651B (zh) * 2004-09-29 2010-06-16 宝生物工程株式会社 用于产生反转录病毒载体的细胞
JPWO2006082958A1 (ja) 2005-02-07 2008-06-26 タカラバイオ株式会社 レトロウイルスの保存方法
EP1892294A4 (de) 2005-06-15 2010-04-14 Takara Bio Inc Verfahren zum transfer von genen in fettzellen oder vorläuferfettzellen
CA2616863A1 (en) * 2005-07-29 2007-02-01 Australian Stem Cell Centre Limited Compositions and methods for growth of pluripotent cells
EP1921136B1 (de) 2005-08-16 2012-12-12 Takara Bio, Inc. Nukleinsäure zur behandlung oder vorbeugung einer immunschwächevirusinfektion
KR101279172B1 (ko) 2005-08-17 2013-06-27 다카라 바이오 가부시키가이샤 림프구의 제조 방법
JP4741906B2 (ja) * 2005-08-31 2011-08-10 タカラバイオ株式会社 リンパ球の製造方法
CA2623735A1 (en) 2005-09-30 2007-04-12 Takara Bio Inc. Method for production of t cell population
KR20090024782A (ko) * 2006-06-09 2009-03-09 다카라 바이오 가부시키가이샤 림프구의 제조 방법
CN101663397B (zh) 2007-04-20 2015-04-22 宝生物工程株式会社 用于基因治疗的载体
EP2267118A4 (de) 2008-03-27 2013-08-28 Takara Bio Inc Verfahren zur herstellung einer transfizierten zelle
WO2010004989A1 (ja) 2008-07-07 2010-01-14 タカラバイオ株式会社 多能性幹細胞の製造方法
WO2010080032A2 (en) * 2009-01-09 2010-07-15 Stichting Het Nederlands Kanker Instituut Bead-assisted viral transduction
JPWO2011024791A1 (ja) 2009-08-25 2013-01-31 タカラバイオ株式会社 レチノイン酸存在下でのｔ細胞集団の製造方法
CN102597223B (zh) 2009-09-11 2017-05-10 宝生物工程株式会社 生产天然杀伤细胞的方法
US9228206B2 (en) 2010-06-30 2016-01-05 Takara Bio Inc. Method for gene transfer
WO2012002452A1 (ja) * 2010-06-30 2012-01-05 タカラバイオ株式会社 遺伝子導入方法
WO2014172309A2 (en) 2013-04-18 2014-10-23 The United States Of America As Represented By The Secretary Of The Army, On Behalf Of The United Therapeutic compositions for neutralizing type i interferons, and methods of use
CN109790536A (zh) 2016-07-29 2019-05-21 宝生物工程株式会社 用于干细胞产生的纤连蛋白片段
US11524988B2 (en) 2016-09-19 2022-12-13 H. Lee Moffitt Cancer Center And Research Institute, Inc. Artificial antigen presenting cells for genetic engineering of immune cells
CN108103045B (zh) * 2016-11-25 2022-10-04 丰益(上海)生物技术研发中心有限公司 脂肪酶及其应用
IL292456B (en) 2017-02-22 2022-08-01 Lumus Ltd Optical assembly of a light guide
US20200181260A1 (en) * 2017-02-22 2020-06-11 H. Lee Moffitt Cancer Center And Research Institute, Inc. Bispecific antibody for cancer immunotherapy
EP3744832A4 (de) 2018-01-25 2021-11-24 Takara Bio Inc. Verfahren zur herstellung von lymphozyten
CN113330348B (zh) 2019-01-24 2023-01-24 鲁姆斯有限公司 包括具有三阶段扩展的loe的光学系统
WO2021138303A1 (en) * 2019-12-30 2021-07-08 Saint-Gobain Performance Plastics Corporation Containers and methods for cell transduction
CN113444167B (zh) * 2021-07-15 2022-09-30 陕西巨子生物技术有限公司 重组人胶原蛋白多肽及其应用
CN114634984A (zh) * 2022-02-02 2022-06-17 复旦大学 一种脑胶质瘤生物标记物mlkl基因及其应用
WO2023213969A1 (en) * 2022-05-05 2023-11-09 Juno Therapeutics Gmbh Viral-binding protein and related reagents, articles, and methods of use
CN114965839A (zh) * 2022-05-11 2022-08-30 朗肽生物制药股份有限公司 人碱性成纤维细胞生长因子的肽图分析方法
US20240167019A1 (en) * 2022-11-18 2024-05-23 Saint-Gobain Performance Plastics Corporation Aptamers, containers and methods for cell transduction
CN117603343B (zh) * 2024-01-19 2024-04-26 四川大学 阻断bFGF的胶原来源天然短肽及应用
CN117645664A (zh) * 2024-01-29 2024-03-05 英特菲尔(成都)生物制品有限责任公司 重组人纤连蛋白标准品及其制备方法、鉴定方法与应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8516421D0 (en) 1985-06-28 1985-07-31 Biotechnology Interface Ltd Fibronectins
US5026839A (en) 1985-12-17 1991-06-25 Synergen, Inc DNA encoding a basic fibroblast growth factor
US4994559A (en) 1985-12-17 1991-02-19 Synergen, Inc. Human basic fibroblast growth factor
JP2770926B2 (ja) * 1985-12-17 1998-07-02 サイナーゲン インコーポレーテッド 毛管内皮細胞プロテアーゼ合成、ｄｎａ合成および遊走を促進することの出来るヒト胎盤血管形成誘導因子
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5492890A (en) * 1990-12-03 1996-02-20 The Scripps Research Institute Polypeptides for promoting cell attachment
DE4110409C2 (de) * 1991-03-29 1999-05-27 Boehringer Ingelheim Int Neue Protein-Polykation-Konjugate
JP2829405B2 (ja) * 1991-10-14 1998-11-25 寳酒造株式会社 機能性ポリペプチド
SE503225C2 (sv) * 1991-10-30 1996-04-22 Leif Lindholm Konsult Ab Virus-antikroppskomplex för införing av virus i mammalieceller
CH685803A5 (fr) * 1992-06-09 1995-10-13 Francis Verdan Bâton d'alun fixé dans un étui.
GB9223084D0 (en) * 1992-11-04 1992-12-16 Imp Cancer Res Tech Compounds to target cells
US5686278A (en) * 1994-03-25 1997-11-11 Indiana University Foundation Methods for enhanced retrovirus-mediated gene transfer
JPH1029952A (ja) 1996-07-16 1998-02-03 Takara Shuzo Co Ltd ヒト免疫不全ウイルス感染の制御用組成物および制御方法

Also Published As

Publication number Publication date
ES2259182T3 (es) 2006-09-16
US20030087437A1 (en) 2003-05-08
KR100353115B1 (ko) 2003-01-06
CN100390290C (zh) 2008-05-28
EA003204B1 (ru) 2003-02-27
CA2235629A1 (en) 1997-05-22
EA199800369A1 (ru) 1998-12-24
AU7505896A (en) 1997-06-05
ATE325884T1 (de) 2006-06-15
KR19990067446A (ko) 1999-08-16
EA200200837A1 (ru) 2002-12-26
US7446170B2 (en) 2008-11-04
US6426042B1 (en) 2002-07-30
US6472204B1 (en) 2002-10-29
US7790849B2 (en) 2010-09-07
US6949623B2 (en) 2005-09-27
DE69636122T2 (de) 2006-12-07
EA004928B1 (ru) 2004-10-28
US20090209730A1 (en) 2009-08-20
AU709831B2 (en) 1999-09-09
EP0870839A1 (de) 1998-10-14
EA200001110A1 (ru) 2001-06-25
WO1997018318A1 (en) 1997-05-22
MX9803706A (es) 1998-09-30
CN1207774A (zh) 1999-02-10
KR100395420B1 (ko) 2003-08-21
JP3343357B2 (ja) 2002-11-11
EP0870839B1 (de) 2006-05-10
US20060030046A1 (en) 2006-02-09
EA003195B1 (ru) 2003-02-27
EP0870839A4 (de) 2000-01-19

Similar Documents

Publication Publication Date Title
DE69636122D1 (de) Verfahren zur einführung von genen in zielzellen mit hilfe von retroviren
ATE345682T1 (de) In vitro verfahren zum einbringen von nukleinsäuren in eine zelle
AU2161501A (en) Immobilized single domain antigen-binding molecules
DE69706187D1 (de) Zusammensetzungen und verfahren zur immobilisierung von nukleinsäure auf festträgern
ATE414171T1 (de) Verfahren zur immobilisierung von oligonukleotiden auf festem trägermaterial
AU2894289A (en) Domain-modified constant region antibodies
DE3673501D1 (de) Mittel und verfahren zur funktionalisierung von nukleinsaeuren.
WO1999016907A3 (en) Reagent and method for attaching target molecules to a surface
DE69637579D1 (de) Methode zur Amplifizierung von Nukleinsäure und entsprechende Regenzien dafür
DE69825002D1 (de) Verfahren zur Verbesserung der Stabilität und/oder Haltbarkeit von verschiedenen Substraten
DE69024447D1 (de) Induzierer einer tumorlysierenden Zelle, Verfahren und Gerät zur Induzierung tumorlysierender Zellen
DE69835813D1 (de) Verfahren zur kultivierung von zellen und zur vermehrung von viren
DE59107591D1 (de) Immobilisierung von organischen makromolekülen oder biopolymeren in einer polymermembran
PT82940A (de) Mit uberzugen versehene formkorper zur bindung von bioaffinen substanzen verfahren zu ihrer herstellung sowie ihre verwendung
EP1083980A4 (de) Modulation molekularer wechselwirkungspositionen in rns und anderen biomolekülen
DE59814359D1 (de) Mikrostrukturierter biosensor, verwendung des biosensors und verfahren zur immobilisierung von biokatalysatoren
ATE247710T1 (de) Genexpression von utrophin
DE69514415D1 (de) Verfahren zur Herstellung von Dioxazinverbindungen,damit gefärbte Materialien und Dioxazinverbindungen mit plattenartiger Kristallform.
ATE389727T1 (de) Modulatoren der expression von morphogenen und deren identifizierungsverfahren
DE59700281D1 (de) Verfahren zur Herstellung von Aminoessigsäuren mit alpha-ständigem tertiären Kohlenwasserstoffrest oder deren Nitrilen
DE69704885D1 (de) Zusammensetzung und Verfahren zur Leimung von flächigen Strukturen
RU2000106030A (ru) Способ воздействия на связывание p53 с геном-мишенью
ATA33696A (de) Verfahren zum immobilisieren von schadstoffen und festkörper mit immobilisierten schadstoffen
AUPO654597A0 (en) Nucleic acid molecules specific for bacterial antigens and uses thereof
ATE55608T1 (de) Mittel und verfahren zur funktionalisierung von nukleinsaeuren.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition